Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naptumomab estafenatox + IFN-alpha in advanced RCC
NCT00420888Phase 3Completed
- Sponsor
- Active Biotech AB
- Start
- Jan 2007
- Primary completion
- Jan 2013
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of naptumomab estafenatox in renal cell carcinoma (RCC) (3 arms), sponsored by Active Biotech AB. Primary endpoint: Time to death up to 18 months. Started Jan 2007; status: completed.
02
Drugs
naptumomab estafenatox
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00420888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420888.